Home > WorldWide Distribution

WorldWide Distribution

Online Order

Thank you for your interest in PerioChip®. For online order, please click the suitable button

WorldWide Distribution

Austria

Dexcel Pharma GmbH - Dexcel Dental Division
Carl-Zeiss-Str. 2
D-63755 Alzenau, Germany

Tel: +43-(0)800-293-628
(Toll free number inside Austria)
Fax: +43-(0)800-293-712
(Toll free number inside Austria)

www.periochip.de

Mrs. Lorena Raub
lorena.raub@dexcel-pharma.de
+49-6023-948047
Germany

Dexcel Pharma GmbH -Dental Division
Carl-Zeiss-Str. 2
D-63755 Alzenau,Germany

Tel: +49-(0)800-284-3742
(Toll free number inside Germany)
Fax: +49-(0)800-732-7120
(Toll free number inside Germany)

www.periochip.de

Mrs. Lorena Raub
lorena.raub@dexcel-pharma.de
+49-6023-948047
Greece

Arriani Pharmaceuticals SA
85 Lavriou Ave. 19002 Peania Athens

Tel: +30-210-668-3210
Fax: +30-210-668-3250

www.arriani.gr

Mrs. Georgia Marnera
marnera@arriani.gr
Ireland

Dexcel Pharma GmbH
Dexcel Pharma GmbH -Dental Division
Carl-Zeiss-Str. 2
D-63755 Alzenau

www.dexceldental.co.uk

Mrs. Nadine Vaeth
nadine.vaeth@dexcel-pharma.de
+49-6023-948048
Israel

Dexcel Pharma
1, Dexcel St. Or Akiva 30600
Israel

Tel: +972-4-636-4030
Fax: +972-4-636-4004

www.dexcel.com

Mrs. Yael Shem-Tov
yael.shemtov@dexcel.com
+972-54-4758923
Italy

Curaden Healthcare SRL
Via Parini, 19
I-21047 Saronno (VA)

Tel: +39 02 9622799
Fax: +39 02 96709243

www.curaden.it

Dr. Andrea Caliendo
a.caliendo@curaden.it
Luxembourg

(Benelux)
Dexcel Pharma GmbH -Dental Division
Carl-Zeiss-Str. 2
D-63755 Alzenau, Germany

www.periochip.de

Mrs. Nadine Vaeth
nadine.vaeth@dexcel-pharma.de
+49-6023-948048
Singapore

AmediusTec Ltd
12 Harper Road
Sulisam Building, Singapore 369677

Tel: +65 7826 5812
Fax: +65-6841-7526

www.apexpharmacy.com.sg/

Mrs. Michelle Foo
Michelle_foo@Amediustec.com
+65 9336 8633
Switzerland

Karr Dental AG
Böhnirainstrasse 9
CH-8800 Thalwil
Switzerland

Tel: +41 44 727 40 00
Fax: +41 44 727 40 10

www.karrdental.ch

Mr. Daniel Gander
D.Gander@karrdental.ch
+41-44- 725-4007
The Netherlands

Dexcel Pharma GmbH -Dental Division
Carl-Zeiss-Str. 2, D-63755 Alzenau
Germany

Tel: +31- (0) 800 - 022- 7321 (Toll free number inside Netherland)
Fax: +31- (0) 800 - 022- 7468 (Toll free number inside Netherland)

www.periochip.de
Mrs. Nadine Vaeth
nadine.vaeth@dexcel-pharma.de
+49-6023-948048
United Kingdom

Dexcel Pharma Ltd.
7 Sopwith Way
Drayton Fields Industrial Estate
Daventry, Northants NN11 8YL, United Kingdom

Tel: : +44-(0)80-82343981
(Toll free number inside UK)
Fax: +44-(0)80-82349604
(Toll free number inside UK)

www.dexceldental.co.uk

Mrs. Ewa Kearl
EwaKearl@dexcelpharma.co.uk
USA

Adrian Pharmaceuticals
5331 Commercial Way - Ste. 211
Spring Hill, Florida 34611, USA

Tel: +1-352-596-6001
Fax: +1-352-597-4427

www.adrianpharma.com

Dr. Bryan T. Marshall
bryan.marshall@adrianpharma.com

PerioChip^® contains 2.5 mg of chlorhexidine gluconate in a biodegradable matrix of hydrolyzed gelatin (cross-linked with glutaraldehyde). PerioChip^® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. PerioChip^® may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing. PerioChip^® is recommended for use in periodontal pockets with a pocket depth (PD) greater than or equal to 5 mm.

For Important Safety Information, click here.

PerioChip^® should not be used in a patient who has a known sensitivity to chlorhexidine or in pregnant women. The use of PerioChip^® in an acutely abscessed periodontal pocket has not been studied and therefore is not recommended. Although rare, infectious events including abscesses and cellulitis, (which have been reported after scaling and root planing alone), have also been reported with the adjunctive placement of the PerioChip post scaling and root planning. Management of patients with periodontal disease should include consideration of potential underlying medical disorders, such as cancer, diabetes, and immunocompromised status. The most frequently observed adverse events in the two pivotal clinical trials were toothache (50.7%), upper respiratory tract infection (28.4%), and headache (27.1%). Toothache was the only adverse reaction that was significantly higher (p = 0.042) in the PerioChip group when compared to placebo.

Patients should avoid flossing near the site of the PerioChip^® insertion for 10 days to avoid dislodging the chip. All other normal oral hygiene habits may continue as usual. There are no restrictions on food or drink after treatment.

Patients should also be advised that although some mild to moderate sensitivity is normal during the first week after placement of PerioChip, if pain, swelling, or other problems occur, dentist should promptly be notified.

The information on this website is based on the US Prescribing Info for the PerioChip® product. If you live outside of the United States, please contact your dentist. Dental professionals located outside of the US should contact their local PerioChip® distributor.

Please see full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

WorldWide Distribution

Online Order

WorldWide Distribution

Austria

Germany

Greece

Ireland

Israel

Italy

Luxembourg

Singapore

Switzerland

The Netherlands

United Kingdom

USA